Glaucoma Trial, Recruiting NCT05370287 Sponsor: Food and Drug Administration (FDA) Condition: Glaucoma
Back to Glaucoma

Glaucoma Trial, Recruiting

NCT05370287
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 21 years of age or older.
  • You are able to follow simple instructions during an eye imaging scan (similar to a standard eye exam).
  • You are able to understand and sign a consent form agreeing to take part.
  • You have been diagnosed with primary open-angle glaucoma, also known as POAG (for one specific group in the trial).

Who may not be able to join:

  • You are under 21 years of age.
  • You have an eye condition that would prevent clear images from being taken, such as difficulty keeping your eye still or cloudiness in the eye (confirm with trial site).
  • Your eyeglass or contact lens prescription is stronger than +4 or weaker than -8 (confirm with trial site).
  • You have had a bad reaction to eye drops that dilate your pupils in the past.
  • You have a narrow drainage angle in your eye or have ever had a sudden, painful type of glaucoma called acute angle closure glaucoma.
  • You do not meet the specific medical definition of primary open-angle glaucoma set by the American Academy of Ophthalmology (for one specific group in the trial).
  • You have a lung or breathing condition such as COPD, emphysema, or asthma that would make it unsafe to receive extra oxygen — this applies only to participants in a specific part of the trial involving blood flow measurements.
  • You rely on oxygen support to breathe, or your blood oxygen level is below 95% — this applies only to participants in the blood flow measurement part of the trial.
  • You have tested positive for COVID-19 at the time of joining, or you have ongoing light sensitivity as a result of having had COVID-19.
  • You work directly under the supervision of Dr. Hammer.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Daniel X Hammer, Ph.D., Food and Drug Administration (FDA)

Phone: 301-796-9320

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Food and Drug Administration (FDA)
Registry
ClinicalTrials.gov
Start date
22 January 2018
Est. completion
30 September 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in Retinal blood flow (RBF) with oxygen inhalation; Retinal ganglion cell (RGC) density; RGC soma diameter; Retinal pigment epithelium (RPE) cell organelle motility; Photoreceptor (PR) cell function

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov